Piper Sandler lowers Becton Dickinson stock price target on growth concerns
#Piper Sandler #Becton Dickinson #Price Target #Medical Technology #Organic Growth #Stock Valuation #Investment Analysis
📌 Key Takeaways
- Piper Sandler reduced the price target for Becton Dickinson from $305 down to $290.
- The financial institution maintained its 'Overweight' rating on the medical tech firm despite the target cut.
- Primary concerns cited by analysts include sluggish organic revenue growth and difficulties in margin expansion.
- The firm faces a combination of stiff competition and macroeconomic pressures affecting its global operations.
📖 Full Retelling
🏷️ Themes
Finance, Healthcare, Stock Market
📚 Related People & Topics
Health technology
Application of organized knowledge and skills to solve health problems
Health technology is defined by the World Health Organization as the "application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures, and systems developed to solve a health problem and improve quality of lives". This includes pharmaceuticals, devices, procedur...
Piper Sandler Companies
American financial services company
Piper Sandler Companies is an American multinational investment bank and financial services company, focused on mergers and acquisitions, financial restructuring, public offerings, public finance, institutional brokerage, investment management, and securities research. Through its principal subsidia...
BD (company)
American biotechnology Company
Becton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas. BD is ranked #211 in the 20...
🔗 Entity Intersection Graph
Connections for Health technology:
- 🌐 Baird (1 shared articles)
- 🏢 Haemonetics (1 shared articles)
- 🏢 Earnings per share (1 shared articles)
- 🏢 BD (company) (1 shared articles)
- 🏢 Earnings report (1 shared articles)
- 🌐 Profit margin (1 shared articles)
- 🏢 Philips (1 shared articles)
- 🌐 Cash flow (1 shared articles)
📄 Original Source Content
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry As Claude disrupts stock market, Anthropic researcher warns ’world is in peril’ Gold, silver prices rise amid U.S.-Iran tensions, blowout January payrolls data Dow halts three-day win streak as blowout jobs data curbs rate cut bets Citi pushes back Fed rate cuts to May after blowout January jobs report (South Africa Philippines Nigeria) Piper Sandler lowers Becton Dickinson stock price target on growth concerns Analyst Ratings Published 02/10/2026, 09:26 AM Piper Sandler lowers Becton Dickinson stock price target on growth concerns 0 BDX 5.21% Investing.com - Piper Sandler has reduced its price target on Becton Dickinson (NYSE:BDX) to $170.00 from $205.00 while maintaining a Neutral rating on the medical technology company. This target sits well below the current stock price of $207.39 and appears conservative compared to InvestingPro ’s Fair Value assessment, which suggests BDX is currently undervalued despite trading at a P/E ratio of 34.29. The adjustment follows Becton Dickinson ’s fiscal first-quarter results, which showed revenue of $5,252 million, representing a 0.4% year-over-year increase on a constant currency basis. This performance exceeded both Wall Street’s expectations of $5,147 million and management’s guidance for low-single-digit organic sales declines. Looking at the broader picture, BDX has achieved 6.22% revenue growth over the last twelve months, with total revenue reaching $21.92 billion. Despite beating revenue estimates, the company posted flat organic growth, with continued pressure in key areas including Alaris, China, and vaccines. Margins declined year-over-year due to tariffs but still came in slightly ahead of consensus, contributing to an earnings per share of $2.91, which beat expectations by ten cents. The company maintains a gross profit margin of 47.95% and has remained profitable with diluted EPS of $6.12 over the last twelve months. Piper Sandler noted that the recently c...